In addition to our investigations of the prognostic values of E2F mRNA expression, we evaluated the association with other clinicopathological characteristics, including correlation of E2Fs with clinical stages, HER2 status, treatment strategies and gender status and differentiation degree of GC patients. This evidence concerns the gene ERBB2 and gastric cancer.